Posted by Michael Wonder on 23 Jul 2022
Vertex advances VX-548 in acute and neuropathic pain
22 July 2022 - Breakthrough therapy designation granted by FDA.
Vertex Pharmaceuticals today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the U.S. FDA, Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in the fourth quarter of 2022.
